Director, HEDIS Policy National Committee for Quality Assurance N/A
Supported by an educational grant from Novo Nordisk Inc.
Note: Lunch will be served in this session
Describe current state of diabetes quality care delivery, particularly the clinical and economic consequences associated with disease complications, iatrogenic hypoglycemia, and comorbidities
Evaluate the efficacy, safety, and implications of available T2DM therapies on achieving glycemic goals while mitigating hypoglycemia risk
Outline the latest guideline-directed HEDIS quality measurement set applicable to diabetes that
emphasize effectiveness of care, access/availability of care, utilization, and patient experience at the practitioner, health system, and health plan levels
Discuss the current and potential future impact of quality improvement efforts, particularly HPA, on diabetes care and patient outcomes